comprehensive -WSS

comprehensive

author：focus 2025-10-02 00:28:54 - browse：5

A person walks past the Palantir sign. -- health tech coverage from STAT — FABRICE COFFRINI/AFP via Getty Images

PALO ALTO, Calif. — At a bustling artificial intelligence conference in June hosted by data heavyweight Palantir, a handful of relative newcomers — hospital executives — milled among government and defense industry customers spiritedly trading new uses for the company’s automation and analytics services.

Palantir is best known for its work in government and intelligence, but early adopters of the company’s nascent health offerings, including leaders from Cleveland Clinic, Tampa General Hospital, and HCA, offered demos and gave keynotes last month explaining applications like sepsis monitoring or staff scheduling tools.

For the hospital systems, it’s an expensive bid to tailor the company’s AI technology to hospital operations — and an attempt to blunt the effects of severe staffing shortages and limited bed space amid a resurgence of in-person care.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： H5N1 bird flu virus started spreading in cows in Texas in December

hotspot

focus

WSS

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Cholera vaccine supply gets boost as demand surges globally

Anthos stroke drug appears safer than common blood thinner

Exact Sciences stock tumbles despite strong cancer detection sales

Element Biosciences CEO lays out genome sequencing strategy

FTC falls short on scrutinizing hospital mergers, study says

explore

comprehensive

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

In key trial, Verve's treatment lowers cholesterol levels in patients

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Affirmative action in medical school literally saved lives

Cell therapy fails to slow type 1 diabetes, but safety is established

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

explore

Astellas still sees hope in its gene therapy after four deaths

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Cholera vaccine supply gets boost as demand surges globally

Wegovy, Zepbound and weight loss drugs that preserve muscle

Cell therapy fails to slow type 1 diabetes, but safety is established

Cue Health's Covid

hotspot

focus

Wikipedia

focus